| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa7c62319c47fa5dd0aaf9105290366e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51845f75a623cc8bf4a511141e7c19a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_461885a172ac9885913ec2ef4e87e1d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d445331b6d1630200f802027f354b00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a539819547ae747c883b89963f4e6c1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8107 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2012-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2558415abdd78d44f21362b48bf20e79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5239e28a9caf6bfa02ec6eda84fad9aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93a90cf1f23c04de67f603240d96dddc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92d7856ad1bb20054d7a8250bc18f9e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_143204a7640a0ecb8d4548be508c1f4d |
| publicationDate |
2013-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013345073-A1 |
| titleOfInvention |
Use of alpha-2-macroglobulin for determining osteonecrosis disease status and for screening therapeutic agents for preventing or treating osteonecrosis |
| abstract |
The present application presents a method of assessing a predisposition to osteonecrosis in an individual based on the level of expression/activity of alpha-2-macroglubulin, a biomarker whose expression is positively correlated with osteonecrosis. Also provided herein are a diagnostic/prognostic system as well as a software product based on the determination of the level of expression/activity of alpha-2-macroglobulin. Screening methods for the determination of usefulness of an agent in the prevention and/or treatment of osteonecrosis are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020232295-A1 |
| priorityDate |
2012-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |